RAGE-binding peptide

RAGE-binding peptide (RBP), also known as RAGE antagonist peptide (RAP), is a synthetic peptide derived from the RAGE-binding domain (amino acids 150–183 segment) of high-mobility group box 1 (HMGB1, also known as amphoterin). It acts as a competitive antagonist of the receptor for advanced glycation end products (RAGE), blocking the interaction of RAGE with its ligands such as HMGB1, S100P, and S100A4. By inhibiting the HMGB1/RAGE signaling pathway, RBP suppresses downstream proinflammatory and proapoptotic cascades, including the NF-κB and ERK1/2 pathways. RBP is being investigated in preclinical studies for various therapeutic applications, including improving islet transplant survival, mitigating acute lung injury and pneumonia, treating ischemic stroke, and suppressing tumor growth and metastasis in glioblastoma and triple-negative breast cancer.

Other names

HMGB1 (150-183) peptideRAGE antagonist peptideRAGE-antagonist peptideRAPRBPamphoterin (150-183) peptide